COMMUNIQUÉS West-GlobeNewswire

Horizon Discovery Enters into License Agreement with US Immuno-Oncology Company
12/02/2018
Horizon Discovery Enters into License Agreement with US Immuno-Oncology Company Horizon out-licenses proprietary cell line and Helitron transposon gene editing technologies demonstrating Horizon's ability to generate [...]
Allergy Therapeutics: Completion of recruitment in PQ Grass Phase II trial
12/02/2018
Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Completion of recruitment in PQ Grass Phase II trial Trial running ahead of schedule with data now due in early H2 2018 12 February 2018 Allergy [...]
Advanced Accelerator Applications Signs Exclusive License Agreement with Cancer Targeted Technology to Develop CTT1057, an F-18 Labeled PSMA Ligand for Diagnostic Applications in Prostate Cancer
12/02/2018
SAINT-GENIS-POUILLY, France, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ: AAAP ) (AAA or the Company), a Novartis company and leader in nuclear medicine theragnostics, today [...]
Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A
12/02/2018
Foundation Fighting Blindness and ProQR enter into a partnership to develop QR-421a for Usher syndrome type 2A, targeting mutations in exon 13 of the causative USH2A gene. Foundation Fighting Blindness will provide [...]
Akcea Therapeutics to Hold Fourth Quarter 2017 Financial Results Webcast
12/02/2018
CAMBRIDGE, Mass., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA ), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious [...]
Axovant Sciences Announces Changes to Management Team and Board of Directors
12/02/2018
Dr. David Hung resigns as CEO and continues as scientific advisor to Roivant family of companies Dr. Pavan Cheruvu appointed as CEO of Axovant Dr. Roger Jeffs, former President and co-CEO of United Therapeutics, and [...]
Evogene Financial Results for the Fourth Quarter and Full Year 2017 Earnings Announcement Schedule
12/02/2018
REHOVOT, Israel, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ: EVGN )(TASE: EVGN ), a leading biotechnology company developing novel products for life science markets through the use of a unique computational [...]
Codexis to Present at the 25th International Molecular Medicine Tri-Conference
12/02/2018
REDWOOD CITY, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS ), a leading protein engineering company, announces that John Nicols, President & CEO, will discuss the development of an improved [...]
Ziopharm Oncology Presents Data on Very Rapid Production of CAR T Cells at Keystone Symposia Emerging Cellular Therapies: T Cells and Beyond
12/02/2018
BOSTON, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP ), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat [...]
ChromaDex Corporation Reports Preliminary 2017 Results
12/02/2018
IRVINE, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ: CDXC ), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way people age, is providing [...]
ContraVir Pharmaceuticals Reaches Agreement with the FDA on the NDA Package for TXL™ Leveraging the 505(b)(2) Regulatory Pathway
12/02/2018
EDISON, N.J., Feb. 12, 2018 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced [...]
Genetic Technologies Limited: Update on Strategic Alliance
12/02/2018
MELBOURNE, Australia, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (NASDAQ: GENE ) (“Company”, “GTG”), wishes to advise that the Company is presently in discussions with the ASX regarding the [...]
Herantis Pharma strengthens team - Outi Lahdenperä and Antti Vuolanto have joined Herantis
12/02/2018
Herantis Pharma strengthens team - Outi Lahdenperä and Antti Vuolanto have joined Herantis Herantis Pharma Plc Press release 12 Feb 2018 at 9:00 am Herantis Pharma plc ("Herantis") has strengthened its core team with [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
12/02/2018
REGULATED INFORMATION GHENT, Belgium, 12 February 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
12/02/2018
REGULATED INFORMATION GHENT, Belgium, 12 February 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]
Adamas Announces New Employment Inducement Grant
09/02/2018
EMERYVILLE, Calif., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS ) today announced that the compensation committee of the company’s board of directors granted five new employees the [...]
Aurora Spine Completes Private Placement
09/02/2018
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. CARLSBAD, Calif., Feb. 09, 2018 (GLOBE [...]
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2018 Ended December 31, 2017
09/02/2018
NORTHVALE, N.J., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP ), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products [...]
Cytori Therapeutics Announces Inducement Grants for New Employees
09/02/2018
SAN DIEGO, Feb. 09, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX ) (the “Company”), announced today that the Compensation Committee of the Company's Board of Directors granted non-qualified stock [...]

Pages